 The first study to evaluate the effects of troglitazone on blood pressure in humans was published recently, which demonstrated a 54 mm Hg reduction in ambulatory blood pressure in 18 nondiabetic obese subjects after 12 weeks treatment. Another study in 18 hypertensive subjects with diabetes mellitus showed an 1812 mm Hg decline in office blood pressure after 8 weeks of treatment. 